Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-TSHR CAR T cell therapy - Innovative Cellular Therapeutics

Drug Profile

Anti-TSHR CAR T cell therapy - Innovative Cellular Therapeutics

Alternative Names: Anti-thyroid stimulating hormone receptor chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics; TSHR CART cell - Innovative Cellular Therapeutics; TSHR CART targeted therapy - Innovative Cellular Therapeutics

Latest Information Update: 14 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovative Cellular Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Thyroid cancer

Most Recent Events

  • 28 Jun 2018 Innovative Cellular Therapeutics initiates enrolment in a phase I trial for Thyroid cancer (Second-line therapy or greater) in China (ChiCTR1800017612)
  • 11 Jun 2018 Innovative Cellular Therapeutics plans a phase trial for Thyroid Cancer (Late-stage disease) in China (ChiCTR1800017637)
  • 01 Dec 2017 Phase-I/II clinical trials in Thyroid cancer (Second-line therapy or greater) in China (Parenteral) (ChiCTR1800014936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top